Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02475213
Recruitment Status : Completed
First Posted : June 18, 2015
Last Update Posted : September 28, 2021
Sponsor:
Information provided by (Responsible Party):
MacroGenics

Brief Summary:
The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC), Urothelial Cancer and other B7-H3 expressing cancers. The study will also evaluate what is the highest dose of enoblituzumab that can be given safely when given with pembrolizumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of MGA271 in combination with pembrolizumab. Safety and efficacy of enoblituzumab in combination with MGA012 (anti-PD-1 monoclonal antibody; also known as INCMGA00012) will also be evaluated.

Condition or disease Intervention/treatment Phase
Melanoma Head and Neck Cancer Non Small Cell Lung Cancer Urethelial Carcinoma Biological: Enoblituzumab Biological: Pembrolizumab Biological: MGA012 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 145 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Actual Study Start Date : July 2015
Actual Primary Completion Date : August 18, 2021
Actual Study Completion Date : August 18, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Cohort 1: enoblituzumab 3 mg/kg plus pembrolizumab 2 mg/kg
enoblituzumab 3 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
Biological: Enoblituzumab
enoblituzumab is administered by IV infusion once per week for up to 51 doses.
Other Name: MGA271

Biological: Pembrolizumab
Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
Other Name: Keytruda

Experimental: Cohort 2: enoblituzumab 10 mg/kg plus pembrolizumab 2 mg/kg
enoblituzumab 10 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
Biological: Enoblituzumab
enoblituzumab is administered by IV infusion once per week for up to 51 doses.
Other Name: MGA271

Biological: Pembrolizumab
Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
Other Name: Keytruda

Experimental: Cohort 3: enoblituzumab 15 mg/kg plus pembrolizumab 2 mg/kg
enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
Biological: Enoblituzumab
enoblituzumab is administered by IV infusion once per week for up to 51 doses.
Other Name: MGA271

Biological: Pembrolizumab
Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
Other Name: Keytruda

Experimental: Cohort 4: enoblituzumab 15 mg/kg plus MGA012 375 mg
enoblituzumab 15 mg/kg IV weekly plus MGA012 375 mg
Biological: Enoblituzumab
enoblituzumab is administered by IV infusion once per week for up to 51 doses.
Other Name: MGA271

Biological: MGA012
anti-PD-1 monoclonal antibody
Other Name: INCMGA00012




Primary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: one year ]
    Adverse Events, Serious Adverse Events


Secondary Outcome Measures :
  1. Peak plasma concentration [ Time Frame: 7 weeks ]
    PK of MGA271 in combination with pembrolizumab

  2. Number of participants that develop anti-drug antibodies [ Time Frame: One year ]
    Proportion of patients who develop anti-MGA271 antibodies, immunogenicity

  3. Change in tumor volume RECIST 1.1 criteria [ Time Frame: Weeks 6, 15, 24, 33, 42, 51 ]
    Anti-tumor activity of MGA271 in combination with pembrolizumab and in combination with MGA012 using both conventional RECIST 1.1.

  4. Change in tumor volume using immune-related RECIST criteria [ Time Frame: Weeks 6, 15, 24, 33, 42, 51 ]
    Anti-tumor activity of MGA271 in combination with pembrolizumab and in combination with MGA012 using immune-related RECIST criteria.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically-proven, unresectable, locally advanced or metastatic melanoma, SCCHN, NSCLC, and other cancers that express B7-H3.
  • Melanoma that has progressed during or following at least 1 and up to 5 prior systemic treatments for unresectable locally advanced or metastatic disease, or melanoma patients who are intolerable of or have refused standard cancer therapy. Pre- and on-study biopsy required.
  • SCCHN that has progressed during or following at least 1 and up to 5 prior systemic treatments for metastatic or recurrent disease deemed to be incurable. Patient who refuse radical resection for recurrent disease or are intolerant of or refused standard first line therapy are eligible to enroll
  • NSCLC that has progressed during or following 1 - 5 prior systemic therapies for unresectable locally advanced or metastatic disease (at least one docetaxel, gemcitabine, or platinum analogue based therapy), or are intolerant of or refused standard cancer therapy. For squamous cell carcinoma, or adenocarcinoma without known activating mutation: the prior systemic therapy is at least one platinum analogue. For adenocarcinoma with known activating driver mutation: the prior systemic therapy is at least TKI directed
  • Urothelial cancer arising in the bladder, renal pelvis, ureter or urethra that has progressed during or following at least 1 and up to 5 prior systemic treatments for unresectable locally advanced or metastatic disease (includes anti-PD-L1,anti-PD-1, but excludes other experimental therapies). Patients must have received at least one platinum-containing regimen (e.g., gemcitabine/cisplatin [GC], dose-dense methotrexate/vinblastine/doxorubicin/cisplatin [DDMVAC], or carboplatinum/gemcitabine). No more than 5 prior systemic regimens allowed.
  • Measurable disease per RECIST 1.1 criteria
  • Easter Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Acceptable laboratory parameters and adequate organ reserve.

Exclusion Criteria:

  • Patients with a history of symptomatic central nervous system metastases, unless treated and asymptomatic
  • Patients with history of autoimmune disease with certain exceptions such as vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic therapy within the past 2 years, patients with history of Grave's disease that are now euthyroid clinically and by lab testing
  • History of allogeneic bone marrow, stem cell, or solid organ transplant
  • Treatment with systemic cancer therapy or investigational therapy within 4 weeks of first study drug administration; radiation within 2 weeks; corticosteroids (greater than or equal to 10 mg prednisone or equivalent per day) or other immune suppressive drugs within 2 weeks of first study drug administration
  • Trauma or major surgery within 4 weeks of first study drug administration
  • History of clinically-significant cardiovascular disease; gastrointestinal perforation; gastrointestinal bleeding, acute pancreatitis or diverticulitis within 4 weeks of first study drug administration
  • Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration
  • Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction (PCR)
  • Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome
  • Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGA271 or pembrolizumab.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02475213


Locations
Show Show 20 study locations
Sponsors and Collaborators
MacroGenics
Investigators
Layout table for investigator information
Study Director: Chet Bohac, PharmD MD MSc MacroGenics
Layout table for additonal information
Responsible Party: MacroGenics
ClinicalTrials.gov Identifier: NCT02475213    
Other Study ID Numbers: CP-MGA271-03
First Posted: June 18, 2015    Key Record Dates
Last Update Posted: September 28, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Melanoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents